The sodium-glucose transport protein 2 (SGLT2) inhibitor empagliflozin and the dipeptidyl peptidase 4 (DPP-4) inhibitor linagliptin are well-established treatments for adults with type 2 diabetes (T2D) [1]. Here, DPP4 is linked to type 2 diabetes mellitus.